Mason Street Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-4,324
| Closed | -$201K | – | 1347 |
|
|
2020
Q4 | $201K | Sell |
4,324
-219
| -5% | -$10.2K | ﹤0.01% | 1414 |
|
|
2020
Q3 | $193K | Buy |
4,543
+741
| +19% | +$31.5K | ﹤0.01% | 1357 |
|
|
2020
Q2 | $182K | Buy |
3,802
+278
| +8% | +$13.3K | ﹤0.01% | 1361 |
|
|
2020
Q1 | $162K | Hold |
3,524
| – | – | ﹤0.01% | 1326 |
|
|
2019
Q4 | $212K | Buy |
3,524
+90
| +3% | +$5.41K | ﹤0.01% | 1372 |
|
|
2019
Q3 | $194K | Sell |
3,434
-5
| -0.1% | -$282 | ﹤0.01% | 1376 |
|
|
2019
Q2 | $191K | Buy |
3,439
+130
| +4% | +$7.22K | ﹤0.01% | 1375 |
|
|
2019
Q1 | $167K | Sell |
3,309
-106
| -3% | -$5.35K | ﹤0.01% | 1446 |
|
|
2018
Q4 | $138K | Buy |
3,415
+114
| +3% | +$4.61K | ﹤0.01% | 1406 |
|
|
2018
Q3 | $229K | Buy |
3,301
+898
| +37% | +$62.3K | ﹤0.01% | 1342 |
|
|
2018
Q2 | $182K | Buy |
2,403
+85
| +4% | +$6.44K | ﹤0.01% | 1398 |
|
|
2018
Q1 | $122K | Buy |
2,318
+145
| +7% | +$7.63K | ﹤0.01% | 1446 |
|
|
2017
Q4 | $116K | Buy |
2,173
+13
| +0.6% | +$694 | ﹤0.01% | 1444 |
|
|
2017
Q3 | $129K | Buy |
2,160
+236
| +12% | +$14.1K | ﹤0.01% | 1414 |
|
|
2017
Q2 | $152K | Buy |
1,924
+29
| +2% | +$2.29K | ﹤0.01% | 1365 |
|
|
2017
Q1 | $157K | Buy |
1,895
+175
| +10% | +$14.5K | ﹤0.01% | 1342 |
|
|
2016
Q4 | $136K | Buy |
1,720
+78
| +5% | +$6.17K | ﹤0.01% | 1361 |
|
|
2016
Q3 | $115K | Buy |
+1,642
| New | +$115K | ﹤0.01% | 1355 |
|